Merck & Co said on Monday it has applied for emergency use authorization in the United States for its oral drug to treat mild-to-moderate patients of COVID-19. The treatment, molnupiravir, has been developed with Ridgeback Biotherapeutics. If authorized, it would be the first oral antiviral medication. Data released last week showed that molnupiravir could halve … Continue reading Merck applies for US authorization of COVID-19 pill